{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Details of toxicity management are further outlined in Section 6.1.8, Toxicity', 'Management.', 'Table 4.', 'Dose Reductions for Blinded Investigational Product (IP)', 'First Dose Reduction', 'Second Dose Reduction', 'Starting Dose', '(Reduce Dose)', '(Reduce Dose)', '0.3 mg/kg', '0.2 mg/kg', '0.1 mg/kg', '70']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Table 5.', 'Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Toxicity', 'First Occurrence', 'Second Occurrence', 'Grade 3 thrombocytopenia lasting more than', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', '7 days', 'Grade 4 thrombocytopenia/Grade 3', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'thrombocytopenia with bleeding/Need for', 'platelet transfusion', 'Grade 4 neutropenia lasting more than 7 days', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 3 febrile neutropenia', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 4 febrile neutropenia', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'Grade 3 Liver Function Tests (LFTs)', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 4 LFTs or Grade 3 LFTs with', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'concomitant Bilirubin Grade 2 or higherb', 'Potential DILI (Drug-induced liver injury)', 'See Section 6.1.8.3', 'See Section 6.1.8.3', 'Grade 3 or 4 hypoalbuminemia', 'Reduce dose to 0.1 mg/kg', 'Discontinue Blinded IP', 'Any other Grade 3 or 4 laboratory', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'abnormality considered clinically significant', 'and treatment-related', 'Grade 2 serosal effusions or edema', 'Reduce to 0.2 mg/kg', 'Reduce to 0.1 mg/kg', 'Grade 3 serosal effusions or edema or', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'Grade 2 capillary leak syndrome', 'Grade 4 serosal effusions or edema or', 'Discontinue Blinded IP', 'N/A', 'Grade > 3 capillary leak syndrome', 'Grade 3 photosensitivity reaction', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'See Section 6.1.8.2', 'See Section 6.1.8.2', 'Grade 4 photosensitivity reaction', 'Discontinue Blinded IP', 'N/A', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Any other Grade 3 or Grade 4 non-laboratory', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'treatment-related toxicity with the exception', 'of fatigue, asthenia, nausea, or other', 'manageable constitutional symptom', 'a.', 'Refer to Appendix H, CTCAE V 4.0 Grading of Relevant AEs for definitions of NCI-CTCAE severity grades and', 'for definition of serosal effusions and edema.', 'b.', 'If potential DILI is suspected please follow guidelines of Section 6.1.8.3.', '71']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.5.5', 'Blinding', '5.5.5.1', 'Blinding of Investigational Product', 'AbbVie, the Investigator, the study site personnel, and subject will remain blinded to each', \"subject's treatment with rovalpituzumab tesirine or placebo and dexamethasone or placebo\", 'and throughout the course of the study.', 'The IRT system will provide access to blinded subject treatment information during the', 'study. AbbVie must then be notified within 24 hours of the blind being broken. The date', 'and reason that the blind was broken must be recorded in the source documentation and', 'eCRF, as applicable.', '5.5.5.2', 'Blinding of Data for Independent Data Monitoring', 'Committee (IDMC)', 'An Independent Data Monitoring Committee (IDMC) will be formed and constituted', 'according to appropriate regulatory guidelines. The IDMC will review the unblinded data', 'from the study with respect to subject accrual, pretreatment characteristics of accrued', 'subjects, the frequency and severity of toxicities and morbidity, and provide', 'recommendations according to the charter. Detailed information regarding the', 'composition of the committee and procedures including frequency of meetings and scope', 'of reviews will be documented in a separate charter. For the futility analysis, OS, other', 'efficacy and safety data will be analyzed and reviewed by the IDMC for recommendation.', '5.5.6', 'Treatment Compliance', 'The investigator or his/her designated and qualified representatives will', 'administer/dispense blinded investigational product only to subjects randomized in the', 'study in accordance with the protocol. The blinded investigational product must not be', 'used for reasons other than that described in the protocol.', 'Blinded investigational product administration must be performed by study site staff and', 'documented in source documents and the eCRF.', '72']\n\n###\n\n", "completion": "END"}